 |
7 Diseases |  |
1 Trial |
|
1 Trial |  |
200 News |  |
| «1234 |
- | Luzu / Bausch Health
Journal: May Measurement Month 2017: analysis of the blood pressure screening results in Ecuador-Americas. (Pubmed Central) - May 4, 2019
...9.3% in people between 18 and 59 years in 2012 [Freire WB, Ramírez-Luzuriaga MJ, Belmont P, Mendieta MJ, Silva-Jaramillo MK, Romero N, Sáenz K, Piñeiros P, Gómez LF, Monge R. Tomo I: Encuesta Nacional de Salud y Nutrición de la población ecuatoriana de cero a 59 años...We identified 446 people with hypertension that were not receiving any treatment and 386 people with uncontrolled hypertension. These results suggest that opportunistic screening can identify significant numbers with raised BP.
- | Luzu / Bausch Health
Journal: Luliconazole, a new antifungal against Candida species isolated from different sources. (Pubmed Central) - Apr 17, 2019
These results suggest that opportunistic screening can identify significant numbers with raised BP. It is concluded that, luliconazole could be an alternative anti-Candida agent, however, in vivo studies must be confirmed usefulness of drug for clinical usage.
- | Luzu / Bausch Health
Preclinical, Journal: In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. (Pubmed Central) - Mar 27, 2019
Overall, LUL and LAN showed the lowest MIC against all isolates of A. flavus. Further studies are required to evaluate the in-vivo efficacy of these agents, and the possibility of using these agents in systemic infections.
- |||| Luzu (luliconazole) / Bausch Health
Trial completion: Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis (clinicaltrials.gov) - Apr 27, 2017
P4, N=75, Completed, Sponsor: Valeant Pharmaceuticals International, Inc.
Further studies are required to evaluate the in-vivo efficacy of these agents, and the possibility of using these agents in systemic infections. Recruiting --> Completed
- | Luzu (luliconazole) / Bausch Health
Trial completion: Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris (clinicaltrials.gov) - Apr 27, 2017
P4, N=30, Completed, Sponsor: Valeant Pharmaceuticals International, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Luzu (luliconazole) / Bausch Health
New P4 trial: Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis (clinicaltrials.gov) - May 11, 2016
P4, N=75, Recruiting, Sponsor: Valeant Pharmaceuticals International, Inc.
- | Luzu (luliconazole) / Bausch Health
New P4 trial: Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris (clinicaltrials.gov) - May 10, 2016
P4, N=30, Active, not recruiting, Sponsor: Valeant Pharmaceuticals International, Inc.
- | Luzu (luliconazole) / Bausch Health
New P4 trial: A Randomized Study Evaluating the Safety and Efficacy of Luliconazole Cream in Pediatric Subjects With Tinea Corporis (clinicaltrials.gov) - Jul 8, 2015
P4, N=75, Not yet recruiting, Sponsor: Valeant Pharmaceuticals
- | Luzu (luliconazole) / Bausch Health
New P4 trial: Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris (clinicaltrials.gov) - Mar 20, 2015
P4, N=20, Recruiting, Sponsor: Bausch & Lomb Incorporated